%20--%3e%3c!DOCTYPE%20svg%20PUBLIC%20'-//W3C//DTD%20SVG%201.1//EN'%20'http://www.w3.org/Graphics/SVG/1.1/DTD/svg11.dtd'%20[%20%3c!ENTITY%20st0%20'fill:%23267E9A;'%3e%3c!ENTITY%20st1%20'fill:%2378C9DA;'%3e%3c!ENTITY%20st2%20'fill:%23FFFFFF;'%3e%3c!ENTITY%20st3%20'fill:%23085580;'%3e%3c!ENTITY%20st4%20'fill:%2386C34A;'%3e%3c!ENTITY%20st5%20'fill:%232FBBCC;'%3e%3c!ENTITY%20st6%20'fill:%234C6F90;'%3e%3c!ENTITY%20st7%20'fill:%23194670;'%3e%3c!ENTITY%20st8%20'fill:%2307557E;'%3e%3c!ENTITY%20st9%20'fill:%23516E89;'%3e%20]%3e%3csvg%20version='1.1'%20id='Layer_1'%20xmlns='http://www.w3.org/2000/svg'%20xmlns:xlink='http://www.w3.org/1999/xlink'%20x='0px'%20y='0px'%20viewBox='0%200%2032%2032'%20style='enable-background:new%200%200%2032%2032;'%20xml:space='preserve'%3e%3cg%3e%3cg%3e%3crect%20x='10.3'%20y='14'%20style='&st5;'%20width='5'%20height='4.4'/%3e%3crect%20x='10.3'%20y='12'%20style='&st5;'%20width='11.4'%20height='1'/%3e%3crect%20x='16.4'%20y='14'%20style='&st5;'%20width='5.3'%20height='0.9'/%3e%3crect%20x='16.4'%20y='15.8'%20style='&st5;'%20width='5.3'%20height='0.9'/%3e%3crect%20x='16.4'%20y='17.5'%20style='&st5;'%20width='5.3'%20height='0.9'/%3e%3crect%20x='16.4'%20y='19.3'%20style='&st5;'%20width='5.3'%20height='0.9'/%3e%3crect%20x='10.3'%20y='19.3'%20style='&st5;'%20width='5'%20height='0.9'/%3e%3cg%3e%3cpath%20style='&st5;'%20d='M22.6,22.3H9.4c-0.6,0-1.2-0.5-1.2-1.2v-10c0-0.6,0.5-1.2,1.2-1.2h13.1c0.6,0,1.2,0.5,1.2,1.2v10%20C23.7,21.7,23.2,22.3,22.6,22.3z%20M9.4,10.8c-0.1,0-0.3,0.1-0.3,0.3v10c0,0.1,0.1,0.3,0.3,0.3h13.1c0.1,0,0.3-0.1,0.3-0.3v-10%20c0-0.1-0.1-0.3-0.3-0.3H9.4z'/%3e%3c/g%3e%3c/g%3e%3cpath%20style='&st5;'%20d='M16,30.2C8.2,30.2,1.8,23.8,1.8,16S8.2,1.8,16,1.8S30.2,8.2,30.2,16S23.8,30.2,16,30.2z%20M16,2.8%20C8.7,2.8,2.8,8.7,2.8,16S8.7,29.2,16,29.2S29.2,23.3,29.2,16S23.3,2.8,16,2.8z'/%3e%3c/g%3e%3c/svg%3e)
Latest Industry News & Trends
Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.
Recently Added News
11/13/2026
BreakingRegulationRetina
US FDA Orders GLP-1 Makers to Warn of Potential for Vision Loss
The US FDA announced Nov. 9 that it would require safety labeling changes for the entire class of glucagon-like peptide-1 (GLP-1) receptor agonists, including the popular weight loss drugs Wegovy a...
11/13/2026
BreakingChinaMyopiaRefractiveRegulationSurgical
Chinese Regulators Approve PT Lunana Phakic IOL from Zeiss for Myopia
German company Carl Zeiss Meditec announced on Nov. 9 that China’s National Medical Products Administration (NMPA) had approved the company’s PT Lunana phakic intraocular lens (IOL). The lens was s...
11/13/2026
BreakingCataractDry EyeGlaucomaIOLPharmaRefractiveRetinaRevenueSurgical
Q3-2026 Ophthalmic Revenue Roundup for Alcon, Harrow, STAAR Surgical, ANI, and Sight Sciences
Alcon reported Nov. 10 that its Q3-2026 net sales were $2.7 billion, a 5 percent increase (+5 percent cc) over $2.6 billion in Q3-2025. Surgical net sales for implantables, consumables, and equipme...
11/13/2026
BreakingMyopiaPharmaRegulation
Santen Gains Korean Marketing Approval for Ryjusea (Atropine) for Myopia
Japan’s Santen Pharmaceutical announced Nov. 2 that it had gained marketing approval in South Korea for preservative-free Ryjusea low-dose atropine drops to slow the progression of pediatric myopia...
11/13/2026
BreakingOptometryRegulationScope of Practice
Alberta Is First Province in Canada to Authorize Optometric Surgery
Alberta on Nov. 1 became the first province in Canada to allow qualified optometrists with additional training to perform certain minor surgical and laser procedures in their offices. Under the exp...
11/13/2026
BreakingPresbyopiaTelehealth
Tenpoint Launches Telehealth Prescribing Option for Yuvezzi Presbyopia Drops
Tenpoint Therapeutics announced Nov. 9 that it was making its presbyopia drop, Yuvezzi, available online through a telehealth platform at orderyuvezzi.com. Tenpoint said the site offers patients a ...
11/13/2026
BreakingDealsEmergingRetina
Emerging Company Imvionix Acquires Rights to Beovu in US, Canada
Imvionix, a privately held emerging retinal pharmaceutical company, announced Nov. 10 that it had acquired exclusive commercial rights to Beovu (brolucizumab-dbll) in the US and Canada from Novarti...
11/13/2026
BreakingRegulationRetina
US FDA Grants Orphan Drug Status to Octant’s Oral RP Candidate
Octant, of Emeryville, California, announced Oct. 27 that the US FDA had granted orphan drug status to OCT-980, an oral treatment candidate targeting retinitis pigmentosa (RP). Orphan drug designat...
11/6/2026
BiosimilarsBreakingCataractDry EyeIOLPharmaRetinaRevenueSurgicalThyroid Eye Disease
Q3-2026 Ophthalmic Revenue Roundup for Regeneron, Amgen, Hoya, Tarsus, RxSight, and Xbrane
Regeneron of Tarrytown, New York, reported Oct. 30 that its Q3-2026 US revenue for Eylea (aflibercept) 2 mg and Eylea HD (a higher dose of aflibercept at 8 mg) was just under $1.1 billion, a 1 perc...
11/6/2026
BreakingPharma
Harrow Launches HarrowRx Platform, Accessible to Doctors Through EMRs
Nashville, Tennessee-based Harrow reported Nov. 2 that it had launched HarrowRx, allowing eye care providers to prescribe all of Harrow’s branded products within their electronic medical record (EM...
11/6/2026
BreakingIndustryPharmaPresbyopia
Lenz Announces Plans for Major Layoffs, CEO Switch
Lenz Therapeutics, of San Diego, California, announced Oct. 28 a strategic reorganization to reduce projected 2027 annual operating expenses by over 50 percent as it continues to roll out Vizz, its...
11/6/2026
BiosimilarsBreakingRegulationRetina
US FDA Approves Ranibizumab (Lucentis) Biosimilar from Xbrane
Sweden’s Xbrane Biopharma announced Oct. 27 that the US FDA had approved its ranibizumab (Lucentis) biosimilar, to be branded Lucamzi in the US. It was approved to treat wet age-related macular deg...
Past News Stories
11/6/2026
BreakingCataractFundingMyopiaRefractive
Global Summit for Eye Health Draws Over $1 Billion in Commitments to Fight Avoidable Blindness
World leaders, international agencies, and private sector partners met in St. John’s, the capital of Antigua and Barbuda, on Nov. 2 at the Global Summit for Eye Health, an event organized by the In...
11/6/2026
BiosimilarsBreakingEuropeRegulationRetina
Ranibizumab Biosimilar from Accord Gains Positive CHMP Opinion
UK-based Accord Healthcare announced Oct. 15 that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) had recommended approval for Fovlussea, its proposed biosimil...
10/30/2026
BreakingClinical TrialMyopiaRegulation
US FDA Advisory Panel Meets to Review Sydnexis’ Rejected Myopia Drop, Hear Public Comments
The US FDA Dermatologic and Ophthalmic Drugs Advisory Committee held a meeting and open public hearing on Oct. 30 in Silver Spring, Maryland, to review the new drug application (NDA) for Sydnexis’ ...
10/30/2026
BreakingCataractEuropeGlaucomaIndiaIndustryMeetingNewsletterRefractiveRetina
2026-2027 Ophthalmic Meetings Calendar
Market Scope regularly updates its list of ophthalmic meetings to keep the information current. Please contact us at matthewdouty@market-scope.com if we do not have your meeting listed. Thank you.
10/30/2026
BreakingCataractDealsIndiaRetinaSurgical
Appasamy Acquires Ruck and its Qube Pro Dual-Function Platform
India’s Appasamy Associates, a portfolio company of Warburg Pincus, reported Oct. 22 that it had acquired German company Ruck, manufacturer of ophthalmic surgical products for both the front and ba...
10/30/2026
BreakingCornealDry EyeGlaucomaIOLLaserPremiumPresbyopiaRetinaRevenue
Q3-2026 Ophthalmic Revenue Roundup for Bausch + Lomb, Glaukos, Novartis, Lumibird, and Lenz
Bausch + Lomb reported Oct. 28 that its Q3-2026 revenue totaled $1.4 billion, a 7 percent increase (+8 percent cc) from $1.3 billion in Q3-2025. Ophthalmic pharmaceuticals segment revenue was $367 ...
10/30/2026
BreakingClinical TrialGene TherapyRegulationRetina
US FDA Gives Green Light to Trial of Opus’ Gene Therapy for RDH12-LCA
Opus Genetics announced on Oct. 21 that the US FDA had signed off on its investigational new drug application, allowing the company to proceed with a clinical trial of OPGx-RDH12, a gene therapy ca...
10/30/2026
BreakingDry EyeStudy
Researchers Develop New Standardized Grading System for MGD
A study published Oct. 6 in Clinical Optometry introduces the Meibomian Gland Composite Score (MGCS)—a standardized grading system that could help clinicians more precisely track meibomian gland dy...
10/30/2026
BreakingDiagnosticLaserRetina
Volk Launches ClearField Pro Lens for Retinal Exams, Laser Treatment
Volk Optical announced Oct. 7 the launch of ClearField Pro, a new ophthalmic lens designed for retinal examination and laser indirect ophthalmoscopy. The lens’ advanced coating provides up to 77 pe...
10/30/2026
BreakingDealsOcular CancerOcular Surface
Visara Gains Exclusive Option to Acquire Candidate for Ocular Surface Squamous Neoplasia
Visara, the ophthalmology subsidiary of NovaBridge Biosciences, announced Oct. 20 that it had gained an exclusive option to acquire worldwide rights to YOLO Immune’s YOL104-2, a candidate for ocula...
10/30/2026
BreakingDiagnosticDigitalGlaucomaPerimetry
RadiusXR, Topcon Introduce InspirePro Wearable Perimeter
RadiusXR and strategic partner Topcon Healthcare introduced the lightweight, wearable InspirePro perimeter at the American Academy of Ophthalmology’s 2026 meeting, held Oct. 10-12 in New Orleans, L...
10/30/2026
BreakingCornealDry EyeRegulation
Stuart Submits IND Amendment to US FDA for Trial of ST-100 in Corneal Wound Healing
Stuart Therapeutics announced Oct. 9 that it had submitted an investigational new drug application (IND) amendment to the US FDA to study its lead candidate, ST-100 (vezocolmitide) eye drops, in co...
Want to Read the Full Article?
Already Have an Account?
Register A Corporate Account
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.